Form 8-K

8-K — Vyome Holdings, Inc

Accession: 0001213900-26-062458

Filed: 2026-05-29

Period: 2026-05-28

CIK: 0001427570

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — ea0292643-8k_vyome.htm (Primary)

EX-99.1 — PRESS RELEASE DATED MAY 28, 2026 (ea029264301ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0292643-8k_vyome.htm · Sequence: 1

false

0001427570

2026-05-28

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

May 28, 2026

VYOME HOLDINGS, INC.

(Exact name of registrant as specified in its

charter)

Delaware

1-37897

26-1828101

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

Harvard Square, One Mifflin Place, Suite 400

Cambridge, MA

02138

(Address of principal executive offices)

(Zip Code)

(949) 429-6680

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b)

of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $0.001 per share

HIND

The Nasdaq Capital Market

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On May 28, 2026, Vyome Holdings, Inc. issued a

press release announcing its financial results for its first fiscal quarter ended March 31, 2026. The full text of the press release is

furnished herewith as Exhibit 99.1.

The information disclosed under this Item 2.02,

including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any registration statement

or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth in such filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No.

Description

99.1

Press Release dated May 28, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VYOME HOLDINGS, INC.

May 29, 2026

By:

/s/ Venkat Nelabhotla

Name:

Venkat Nelabhotla

Title:

President & Chief Executive Officer

EX-99.1 — PRESS RELEASE DATED MAY 28, 2026

EX-99.1

Filename: ea029264301ex99-1.htm · Sequence: 2

Exhibit 99.1

Vyome

Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet

● Vyome

has signed an agreement with Impetis Biosciences Limited, a TATA Enterprise, to in-license

two selective JAK inhibitor assets, opening access to a large and growing ~$57B global market1

● VT-1953

regulatory submissions to the FDA for Orphan Drug Designation status and proposals for constructive

FDA guidance on the next steps of development

● Company

ends Q1 2026 with approximately $8.8 million in cash and cash equivalents while maintaining

a clean capital structure with no debt, no preferred stock, and no toxic financing instruments

CAMBRIDGE,

Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (Nasdaq: HIND)(“Vyome”), a clinical-stage biopharmaceutical company focused

on immuno-inflammatory and rare disease conditions, today reports financial results for the first quarter ended March 31, 2026, and provides

a corporate update.

Krishna

Gupta, Chairman of Vyome, said, “Over the last several quarters, Vyome has executed with focus and discipline, advancing differentiated

programs in areas of significant unmet medical need focused on inflammatory disorders. Inflammation remains one of the world’s

largest problems, and we believe Vyome is well positioned for long-term value creation. We continue to strengthen our scientific, operational,

and governance foundation while remaining highly disciplined on capital structure and shareholder alignment.”

Venkat

Nelabhotla, CEO of Vyome, stated, “We continue to advance VT-1953 toward pivotal-stage readiness while maintaining a strong focus

on disciplined execution, regulatory engagement, manufacturing preparedness, and financial stewardship. We submitted to the FDA an application

for the approval of orphan drug designation status and proposals across several areas of the next stages of development readiness, and

continue to believe VT-1953 addresses a major unmet need in malignant fungating wounds, where there are currently no FDA-approved therapies

specifically addressing the condition.”

“Importantly,

we have continued to preserve what we believe is one of the Company’s key differentiators: a clean and disciplined capital structure

with no debt, no preferred stock, and no toxic financing instruments. We remain focused on creating long-term shareholder value while

advancing our immuno-inflammatory and rare disease strategy,” concluded Mr. Nelabhotla.

1 https://www.researchandmarkets.com/report/jak-inhibitor?srsltid=AfmBOoonOb9NkQoIR8mj_k-Nb-XVnCirMY73UDt2qTp7k7IFfvbe41hi

First

Quarter 2026 and Recent Corporate Highlights

● Regulatory

submissions with the FDA related to VT-1953 pivotal development readiness, including discussions

involving manufacturing, toxicology, pharmacokinetic requirements, and clinical development

considerations. Filed an Orphan Drug Designation application with the FDA

● Continued

advancement of VT-1953 for malignant fungating wounds, a condition associated with significant

unmet medical need and no FDA-approved therapies specifically addressing the condition.

● Raised

approximately $5.29 million in gross proceeds through the sale of 1,089,545 common shares

on January 27, 2026, at an average price of $5.00 per share, representing a 59.2% premium

to the prior day’s closing price, with total dilution to existing shareholders of approximately

15%

● Continued

scientific and translational activities supporting VT-1908 and broader immuno-inflammatory

initiatives

● Presented

positive VT-1953 Phase 2 clinical study data at the prestigious American Association for Cancer Research (AACR) 2026

● Entered

into a strategic in-licensing agreement with Impetis Biosciences Limited, a TATA Enterprise,

for selective JAK inhibitor assets under a capital-light structure with payments at commercialization,

and development using non-dilutive pathways

Financial

Results for the Quarter Ended March 31, 2026

● Cash

and cash equivalents were approximately $8.8 million as of March 31, 2026, compared with approximately $5.0 million as of December 31,

2025

● Total

assets were approximately $10.2 million as of March 31, 2026

● Total

stockholders’ equity was approximately $8.0 million as of March 31, 2026

● Total

operating expenses for the quarter ended March 31, 2026, were approximately $1.1 million, including approximately $666,000 in research

and development expenses and approximately $478,000 in selling, general, and administrative expenses

● Net

loss attributable to common shareholders for the quarter ended March 31, 2026, was approximately $963,000, or approximately $0.15 per

basic and diluted share

The

Company will also host a conference call and webcast on Wednesday, June 3, 2026, at 11:00 a.m. ET to discuss the results. To access the

webcast, please use the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=531gpp9T or dial in at 1-877-317-6789

(U.S./Canada toll-free) or +1-412-317-6789 (international).

replay will be available on the Company Website.

About

Vyome Holdings, Inc.:

Vyome is

building the world’s premier platform spanning the US-India innovation corridor. Vyome’s immediate focus is on leveraging

its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science

and its unique positioning, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global

standards of quality and safety.

To learn

more, please visit www.vyometx.com

Forward-Looking

Statements

Certain statements

made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions

of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,”

“believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,”

“would,” “positioned,” “future,” “forecast,” “intend,” “plan,”

“project,” “outlook,” and other similar expressions that predict or indicate future events or trends or that

are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release

relating to Vyome’s business strategy, the anticipated timing and outcome of regulatory submissions to the FDA, Vyome’s future

operating results, and liquidity and capital resources outlook. Forward-looking statements are based on Vyome’s current expectations

and assumptions regarding Vyome’s business, the economy, and other future conditions. Because forward-looking statements relate

to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Vyome’s

actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical

fact nor guarantees of assurance of future performance. Vyome cautions you, therefore, against relying on any of these forward-looking

statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include,

without limitation, Vyome’s ability to raise capital to fund continuing operations; our ability to protect Vyome’s intellectual

property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and

products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; and other factors

relating to Vyome’s industry, operations and results of operations described in the Vyome’s Annual Report on Form 10-K for

the year ended December 31, 2025, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and subsequent filings with the

Securities and Exchange Commission. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended,

or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible

for Vyome to predict all of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes

no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of

this release, except as may be required under applicable securities law.

SUMMARY

FINANCIAL STATEMENTS

SUMMARY

OF CONDENSED CONSOLIDATED BALANCE SHEETS AS OF

March 31,

2026

December 31,

2025

Cash and cash equivalents

$ 8,795,783

$ 4,982,333

Other current assets

366,799

455,988

Long term assets

1,022,864

1,058,856

Total assets

$ 10,185,446

$ 6,497,177

Liabilities

$ 2,144,125

$ 2,735,160

Total Stockholders’ equity (deficit)

8,041,321

3,762,017

Total liabilities and stockholders’ equity

$ 10,185,446

$ 6,497,177

SUMMARY

OF CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three

months

ended

March 31,

2026

Three

months

ended

March 31,

2025

Revenues

$ 31,591

$ 198,581

Cost of goods sold

(14,946 )

(44,162 )

Gross profit

16,645

154,419

Operating expenses

1,146,585

353,417

Operating loss

(1,129,940 )

(198,998 )

Interest and other expenses, net

144,419

(94,976 )

Net loss

$ (985,521 )

$ (293,974 )

Contacts

Media:

contact@vyometx.com

Visit

us on social media:

Facebook

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

May 28, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 28, 2026

Entity File Number

1-37897

Entity Registrant Name

VYOME HOLDINGS, INC.

Entity Central Index Key

0001427570

Entity Tax Identification Number

26-1828101

Entity Incorporation, State or Country Code

Entity Address, Address Line One

Harvard Square

Entity Address, Address Line Two

One Mifflin Place

Entity Address, Address Line Three

Suite 400

Entity Address, City or Town

Cambridge

Entity Address, State or Province

Entity Address, Postal Zip Code

02138

City Area Code

949

Local Phone Number

429-6680

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.001 per share

Trading Symbol

HIND

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 3 such as an Office Park

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine3

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration